Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H40N2O5.ClH |
Molecular Weight | 521.089 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C
InChI
InChIKey=OKCRIUNHEQSXFD-UHFFFAOYSA-N
InChI=1S/C28H40N2O5.ClH/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5;/h10-11,16-18,20H,9,12-15H2,1-8H3;1H
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/7510624
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7510624
Gallopamil is a L-type calcium channel blocker designed for the treatment of coronary heart diseases: angina pectoris, prinzmetal angina and hypertonia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7510624 |
5.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROCORUM Approved UseUnknown |
|||
Primary | PROCORUM Approved UseUnknown |
|||
Primary | PROCORUM Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris. | 1987 |
|
Initial and sustained phases of myogenic response of rat mesenteric small arteries. | 2001 Nov |
|
A large sustained Ca2+ elevation occurs in unstimulated spines during the LTP pairing protocol but does not change synaptic strength. | 2002 |
|
An increase in extracellular Ca(2+) concentration induces pigment aggregation in teleostean melanophores. | 2002 Aug |
|
Two types of ventricular fibrillation in isolated rabbit hearts: importance of excitability and action potential duration restitution. | 2002 Oct 1 |
|
Role of sarcoplasmic reticulum Ca2+ content in Ca2+ entry of bovine airway smooth muscle cells. | 2003 Oct |
|
[L-type calcium channels involvement in aortic smooth muscle contraction as revealed by membrane potential and active force dynamics]. | 2004 Apr-Jun |
|
Opposite effects of a single IIIS5 mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels. | 2004 Dec 31 |
|
Changes in calcium signalling, gravitropism, and statocyte ultrastructure in pea roots induced by calcium channel blockers. | 2004 Jul |
|
Non-cross-bridge calcium-dependent stiffness in frog muscle fibers. | 2004 Jun |
|
Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones. | 2004 Oct |
|
Mechanisms of potassium- and capsaicin-induced axonal calcitonin gene-related peptide release: involvement of L- and T-type calcium channels and TRPV1 but not sodium channels. | 2008 Feb 6 |
|
Structural model for phenylalkylamine binding to L-type calcium channels. | 2009 Oct 9 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6367415
150 mg/day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
56949-75-8
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
SUPERSEDED | |||
|
439837
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | RxNorm | ||
|
16662-46-7
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
274966
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
C83726
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
VT4VR32A0T
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
240-704-7
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
DBSALT002564
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
119442
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
m5656
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID2047858
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
100000092331
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY | |||
|
SUB02309MIG
Created by
admin on Fri Dec 15 15:12:47 UTC 2023 , Edited by admin on Fri Dec 15 15:12:47 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD